We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Teva and subsidiary Cephalon’s pay-for-delay agreement deprived patients of more affordable medicines
Teva allegations add to debate about high US prices
Department of Justice says Israeli drugmaker conspired to push up prices of generic medicines
Shortages of antimalarials and inhalers feared as purchases spike
Drugmaker’s shares rise after earnings give hope that two-year overhaul will pay off
Israeli drugmaker reports widening quarterly loss but lifts outlook
Four plaintiffs aim to persuade others to sign on to framework
First federal lawsuit to proceed after local governments call offer ‘inadequate’
Drugmaker’s earnings better than expected but investors nervous about potential liabilities
Pharmaceuticals company settles ahead of trial over state’s drugs crisis
Schultz likens claims against drugmakers to blaming drunk driving on makers of alcoholic drinks
World’s biggest generic drugmaker cautions that sales and profits will be lower
Ruling allows launch of rival to Mylan’s allergy injector
Teva is now a value play even if the boss is not paying attention
Israeli drugmaker’s shares drop as competition to top drug Copaxone bites
Pfizer among those risking backlash with new year increases on many medicines
Problem is that some things are cheap for a reason
Backlash feared from customers and politicians as Israeli drugmaker rejigs ailing operations
CEO Kåre Schultz says cuts will be made carefully and ‘not in a harvest way’
International Edition
